Table 2 Genes expression of TAM in relationship with clinicopathological factors

age

   <58

26

31.3(3.05-530.3)

0.252

10.9(0.9-51.9)

0.41

   ≥58

37

30.5(0.6-511.6)

14.5(0.6-69.1)

Gender

   Male

40

31.3(1.3-530.3)

0.607

14.9(0.9-69.1)

0.061

   Female

23

19.9(0.6-426.1)

10.1(0.6-37.9)

Smoking history

   Never

29

30.5(0.6-426.1)

0.699

10.1(0.6-51.9)

0.067

   Former or current

34

31.2(1.3-530.3)

14.9(1.5-69.1)

Histology

   Adenocarcinoma

34

42.9(0.6-530.3)

0.045

12.7(0.6-69.1)

0.41

   Squamous cell carcinoma

20

17.1(1.3-354.3)

16.6(1.5-41.7)

   Others

9

41.2(6.4-511.6)

10.2(4.2-26.7)

Pathological stage

   Stage I

30

9.7(0.6-140.8)

0.016

13.1(0.6-69.1)

0.066

   StageII

11

28.9(1.8-511.6)

13.6(3.1-41.7)

   StageIII

17

177.7(23.5-530.3)

11.8(1.2-51.9)

   StageIV

5

249.9(55.4-429.9)

10.1(3.6-25.9)

T status

   T1

15

4.1(0.6-263.6)

<0.0001

9.9(0.6-22.7)

0.037

   T2-3

48

42.9(1.6-530.3)

14.2(0.9-69.1)

Lymph node metastasis

   N(+)

21

119.1(6.1-530.3)

<0.0001

13.6(1.2-46.9)

0.466

   N(-)

42

19.2(0.6-273.8)

11.1(0.6-69.1)

Lymphovascular invasion

   LVI(+)

12

93.1(6.2-530.3)

0.01

14.2(0.9-37.8)

0.92

   LVI(-)

51

26.5(0.6-429.9)

11.1(0.6-69.1)

Pleural invasion

   PL(+)

20

55.8(14.9-530.3)

0.002

14.2(0.9-69.1)

0.376

   PL(-)

43

19.9(0.6-354.9)

11.1(0.6-51.9)

Differentiation

   Well or Moderately

30

17.3(0.6-429.9)

0.001

13.0(0.6-69.1)

0.961

   poorly

26

113.1(1.6-530.3)

11.9(1.2-37.9)